首页> 中文期刊> 《转化神经变性病(英文)》 >Intranasal rapamycin ameliorates Alzheimerlike cognitive decline in a mouse model of Down syndrome

Intranasal rapamycin ameliorates Alzheimerlike cognitive decline in a mouse model of Down syndrome

         

摘要

Background:Down syndrome(DS)individuals,by the age of 40s,are at increased risk to develop Alzheimer-like dementia,with deposition in brain of senile plaques and neurofibrillary tangles.Our laboratory recently demonstrated the disturbance of PI3K/AKT/mTOR axis in DS brain,prior and after the development of Alzheimer Disease(AD).The aberrant modulation of the mTOR signalling in DS and AD age-related cognitive decline affects crucial neuronal pathways,including insulin signaling and autophagy,involved in pathology onset and progression.Within this context,the therapeutic use of mTOR-inhibitors may prevent/attenuate the neurodegenerative phenomena.By our work we aimed to rescue mTOR signalling in DS mice by a novel rapamycin intranasal administration protocol(InRapa)that maximizes brain delivery and reduce systemic side effects.Methods:Ts65Dn mice were administered with InRapa for 12 weeks,starting at 6 months of age demonstrating,at the end of the treatment by radial arms maze and novel object recognition testing,rescued cognition.Results:The analysis of mTOR signalling,after InRapa,demonstrated in Ts65Dn mice hippocampus the inhibition of mTOR(reduced to physiological levels),which led,through the rescue of autophagy and insulin signalling,to reduced APP levels,APP processing and APP metabolites production,as well as,to reduced tau hyperphosphorylation.In addition,a reduction of oxidative stress markers was also observed.Discussion:These findings demonstrate that chronic InRapa administration is able to exert a neuroprotective effect on Ts65Dn hippocampus by reducing AD pathological hallmarks and by restoring protein homeostasis,thus ultimately resulting in improved cognition.Results are discussed in term of a potential novel targeted therapeutic approach to reduce cognitive decline and AD-like neuropathology in DS individuals.

著录项

  • 来源
    《转化神经变性病(英文)》 |2018年第1期|P.285-306|共22页
  • 作者单位

    Department of Biochemical Sciences Sapienza University of Rome P.le Aldo Moro 5 00185 Rome Italy;

    Department of Biochemical Sciences Sapienza University of Rome P.le Aldo Moro 5 00185 Rome Italy;

    Department of Biochemical Sciences Sapienza University of Rome P.le Aldo Moro 5 00185 Rome ItalyUniversidad Autònoma de Chile Instituto de Ciencias Biomédicas Facultad de alud Avenida Pedro de Valdivia 425 Providencia Santiago Chile;

    Department of Biochemical Sciences Sapienza University of Rome P.le Aldo Moro 5 00185 Rome Italy;

    Department of Biochemical Sciences Sapienza University of Rome P.le Aldo Moro 5 00185 Rome Italy;

    Department of Biochemical Sciences Sapienza University of Rome P.le Aldo Moro 5 00185 Rome Italy;

    Department of Biochemical Sciences Sapienza University of Rome P.le Aldo Moro 5 00185 Rome Italy;

    Department of Chemistry and Sanders-Brown Center on Aging University of Kentucky Lexington KY 40506-0055 USA;

    Department of Biochemical Sciences Sapienza University of Rome P.le Aldo Moro 5 00185 Rome Italy;

    Department of Biochemical Sciences Sapienza University of Rome P.le Aldo Moro 5 00185 Rome Italy;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 肿瘤学;
  • 关键词

    mTOR; Autophagy; Rapamycin; Down syndrome; Alzheimer disease; APP; Tau; Oxidative stress;

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号